Yeongnam University Hospital
Welcome,         Profile    Billing    Logout  
 25 Trials 
18 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Min Chan
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting
3
504
Europe, US, RoW
Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone
Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma
07/30
11/30
SRF388-201, NCT05359861: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Active, not recruiting
2
134
US, RoW
SRF388, Atezolizumab, Tecentriq, Bevacizumab, Avastin, Placebo
Coherus Biosciences, Inc.
Hepatocellular Carcinoma
05/25
05/26
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Recruiting
1/2
110
US, RoW
EU101
Eutilex
Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer
09/25
12/25
BOLD-100-001, NCT04421820 / 2022-003079-41: BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours

Recruiting
1/2
220
Europe, Canada, US, RoW
BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion), BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)
Bold Therapeutics, Inc., Bold Therapeutics, Inc. (Bold)
Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
06/26
09/26
NCT05113693: Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393

Completed
1
33
RoW
CKD-393, CKD-501, D759, H053
Chong Kun Dang Pharmaceutical
Type 2 Diabetes
12/21
12/21
NCT05113849: Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)

Recruiting
1
40
RoW
IN-B009 (Low-dose), IN-B009 (High-dose)
HK inno.N Corporation
COVID-19
02/23
02/23
PLOTS, NCT04066699: Percutaneous Localization: Open-label Registry of Thoracic Surgery

Completed
N/A
70
US
Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools., SPiN Thoracic Navigation System™, Veran System
Veran Medical Technologies
Lung Lesion(s) Requiring Evaluation, Pulmonary Metastasis, Pulmonary Nodule, Solitary, Peripheral Lung Lesions
01/23
02/23
VISION, NCT04151615: VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma

Completed
N/A
203
RoW
Boryung Pharmaceutical Co., Ltd
Multiple Myeloma
01/23
01/23
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
NCT06537752: A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients

Recruiting
N/A
1052
RoW
Boryung Pharmaceutical Co., Ltd
Breast Cancer
10/26
10/26
NCT05493904: PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)

Recruiting
N/A
320
RoW
OCT-guided PCI, Angiography-guided PCI, Drug-eluting stent
Chonnam National University Hospital, Abbott Medical Devices
Coronary Artery Disease, Angina Pectoris
08/24
12/26
RETHINK REFLUX, NCT04253392: Registry

Active, not recruiting
N/A
500
Europe, US, RoW
LINX Reflux Management System, LINX
Ethicon Endo-Surgery
Gastroesophageal Reflux
07/32
07/32
NCT04174157: Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Recruiting
N/A
700
Europe, Japan, US, RoW
Prospective observational registry, Zolgensma
Novartis Pharmaceuticals, United BioSource, LLC
Spinal Muscular Atrophy (SMA)
06/38
06/38
Won, Kyu Chang
NCT05400317: A Study to Evaluate the Efficacy and Safety of AD-218

Recruiting
3
520
RoW
AD-218, AD-218A
Addpharma Inc.
Mixed Dyslipidemia
03/25
06/25
REMATCH, NCT06627322: A Registry-based Randomized Controlled Trial in Type 2 Diabetes with Cardiovascular Risk Factors

Not yet recruiting
N/A
5776
RoW
Dual-combination therapy, Triple-combination therapy, Dexcom G7, Pasta
Kyu Chang Won, Boryung Pharmaceutical Co., Ltd, Dong-A ST Co., Ltd., HK inno.N Corporation, Daewoong Pharmaceutical Co. LTD., Chong Kun Dang Pharmaceutical Corp., Celltrion
Type 2 Diabetes
09/29
09/29

Download Options